On the evening of November 18, Guangshengtang (300436) issued an announcement stating that GST-HG171, an innovative drug, a subsidiary of Guangsheng Zhonglin, an oral small molecule broad-spectrum anti-novel coronavirus 3CL protease inhibitor, recently launched a research initiated by researchers (IIT study). Among them, the research initiator The First Affiliated Hospital of Guangzhou Medical University is undergoing an ethical review process, and Shenzhen Third People's Hospital has been approved by the Ethics Committee and agreed to carry out the study.
announcement shows that at present, the clinical phase I of the broad-spectrum anti-new crown oral small molecule innovative drug GST-HG171 tablet is progressing smoothly, supporting the promotion of IIT research, and applying for registration clinical research based on the above two clinical research data. The company is preparing for this and actively assumes responsibility for epidemic prevention.
At the same time, Guangshengtang reminded of the risks. The GST-HG171 project has obtained research data and needs complete clinical research and approved by the national drug review department before it can be launched. The future epidemic situation and clinical research progress, research results and review and approval results are uncertain. new drug research and development is characterized by long cycle, high risk and high investment.
2022 third quarter report shows that Guangshengtang's operating income in the first three quarters was 297 million yuan, an increase of 9.74% over the same period last year; 's net profit attributable to shareholders of listed companies was -71.493 million yuan , an increase in losses compared with the same period last year. During the reporting period, the company's R&D expenses were RMB 120 million, an increase of 169.27% over the same period last year, mainly due to the significant increase in expenditure on innovative drugs in the reporting period; investment income was RMB 56.0283 million, an increase of 155.99% over the same period last year, mainly due to the increase in profits of Fujian Boao Medical Laboratory Co., Ltd., a joint venture company in the reporting period.
As of the close of the 18th, Guangshengtang was 46.98 yuan per share, down more than 4%, with a total market value of 7.482 billion yuan.
Source: Duchuang Finance Comprehensive
Review: Sun Shijian
